مباشر

RecursionA Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions - Yahoo Finance 10x Genomics Blog10x, Curio Settle Genomics Patent Suit Before Trial - Law360 10x Genomics Blog10x Genomics (TXG) Loss Reduction To US$0.35 TTM EPS Challenges Bearish Profitability Narrative - simplywall.st RecursionRecursion Milestones Link AI Discovery To Clinical And Valuation Upside - Yahoo Finance WuXi BiologicsWuXi Biologics Chengdu Milestone Raises Questions On Capacity Use And Returns - simplywall.st 10x Genomics NewsWhy 10x Genomics (TXG) Stock Is Down Today - StockStory Intuitive SurgicalBetter Than Intuitive Surgical? 1 Under-the-Radar Healthcare Stock to Buy and Hold Forever - The Globe and Mail 10x Genomics BlogWhy 10x Genomics (TXG) stock is down today - MSN Edwards LifesciencesEdwards Lifesciences Stock (US28176E1082): Analyst Upgrade and Price Target Revision - AD HOC NEWS FierceBiotechTrump plans to fire FDA chief Marty Makary: report 10x Genomics BlogHarvard, 10x Patent Suit Targets Newer Cell-Mapping Platform - Bloomberg Law News

BioWorld ٨ مايو ٢٠٢٦

Hangzhou Bio Sincerity Pharma-Tech identifies new exportin-1 receptor antagonists

Hangzhou Bio Sincerity Pharma-Tech Co. Ltd. has reported crylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists found to be useful for the t...

Hangzhou Bio Sincerity Pharma-Tech Co. Ltd. has reported crylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists found to be useful for the treatment of cancer.